Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope Share
SHARE YOUR STORY!
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
Menu
  • About
    • Meet Our Contributors
    • Meet Our Partners
    • Meet the Patient Worthy Team
    • Collaborative Content On Patient Worthy
  • Diseases
  • Share Your Story
    • Patient Worthy Content Submission Guidelines
    • Patient Worthy Writing Prompts
    • Submit Your Story
    • Patient Stories
  • Resources
    • Library
    • Events
    • Patient Worthy FAQs
  • Podcast
  • Contact
  • Join PW

Daily Archives: March 29, 2022

  1. Home>
  2. 2022>
  3. March>
  4. 29
New Immunotherapy Strategy Targets Hard-to-Treat Pancreatic Cancer

New Immunotherapy Strategy Targets Hard-to-Treat Pancreatic Cancer

  • Post author:Kendall Mason
  • Post published:March 29, 2022
  • Post category:Pancreatic Cancer

Pancreatic cancer is typically a difficult cancer to treat, leading to poor outcomes and high mortality rates. One of the reasons for this is the difficulty of diagnosis; it often…

Continue Reading New Immunotherapy Strategy Targets Hard-to-Treat Pancreatic Cancer
A Sensitivity to Certain Sounds May Be Due to Misophonia

A Sensitivity to Certain Sounds May Be Due to Misophonia

  • Post author:Alyssa Stevens
  • Post published:March 29, 2022
  • Post category:Misophonia

According to a recent article, researchers have found that a sensitivity to sounds such as chewing or breathing may actually be caused by misophonia. Misophonia Misophonia, which literally translates to…

Continue Reading A Sensitivity to Certain Sounds May Be Due to Misophonia
NDA Submitted for Sparsentan, an IgA Nephropathy Treatment

NDA Submitted for Sparsentan, an IgA Nephropathy Treatment

  • Post author:Kendall Mason
  • Post published:March 29, 2022
  • Post category:IgA Nephropathy/Proteinuria

Sparsentan is a dual endothelin angiotensin receptor antagonist (DEARA) currently being developed for the treatment of IgA nephropathy (IgAN). The newest update on sparsentan was recently shared by Travere Therapeutics via…

Continue Reading NDA Submitted for Sparsentan, an IgA Nephropathy Treatment
Is Gene Editing The Path Forward to Treat Mitochondrial Diseases?

Is Gene Editing The Path Forward to Treat Mitochondrial Diseases?

  • Post author:Rose Duesterwald
  • Post published:March 29, 2022
  • Post category:Mitochondrial Disease

Mitochondria are called the ‘batteries’ that send power to our body’s cells. They convert energy from food into forms that cells can utilize. Mitochondria contain 0.1% of mitochondrial DNA (mtDNA)…

Continue Reading Is Gene Editing The Path Forward to Treat Mitochondrial Diseases?
Study: Preemptive Gene Testing Benefits Rare Disease Patients

Study: Preemptive Gene Testing Benefits Rare Disease Patients

  • Post author:Kendall Mason
  • Post published:March 29, 2022
  • Post category:Rare Disease

For many rare diseases, the symptoms and experiences of patients are variable. It's extremely rare - if possible at all - to see a rare disease that can be be…

Continue Reading Study: Preemptive Gene Testing Benefits Rare Disease Patients
$1 Million Combined Grant Given to Study RET-Positive Lung Cancer
Photo by Robina Weermeijer on Unsplash

$1 Million Combined Grant Given to Study RET-Positive Lung Cancer

  • Post author:Alyssa Stevens
  • Post published:March 29, 2022
  • Post category:Cancer

According to a recent article, the Hamoui Foundation and LUNGevity Foundation granted $1 million to three researchers in order to study RET-positive lung cancer. RET-Positive Lung Cancer There are two…

Continue Reading $1 Million Combined Grant Given to Study RET-Positive Lung Cancer

Featured


Picture of Family


Metastatic Breast Cancer: Navigating Grief


Picture of Ralph Family walking


Rethinking What It Means to Live With Acromegaly


Illustration of mentor program members


The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

SHARE YOUR STORY!
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Notice
Privacy Policy for CA Residents
EU/UK Privacy Notice
Data Privacy Framework: Consumer Privacy Policy
Consumer Health Data Privacy Policy
Cookie Notice

Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope

© Copyright 2024 Patient Worthy

Sign Up With a Patient Worthy Account and Share Your Rare Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info

We're Happy You're Here!

What best describes you when it comes to rare disease? (check all that apply)

What rare disease(s)/conditions are most important to you?

Visit Home Page or

Thank you for signing up for a Patient Worthy Account!

Have a rare disease story to share? Let us know

Share Story

- OR -

Sign Up For Our Patient Panel

Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.

More Info